Demo

2445 Articles Matching "therapy"

Pear's digital therapeutic reSET-O FDA cleared to treat opioid use disorder

Dec 11, 2018 laura.lovett@himssmedia.com (Laura Lovett), Mobile Health News
The prescription digital therapeutic will give users interactive therapy lessons to be use by patients under a clinician's supervision. ...
Read more

AstraZeneca's Imfinzi fails to meet main goals in head and neck cancer study

Dec 08, 2018 , Reuters
AstraZeneca Plc's immunotherapy treatment Imfinzi did not meet the main goals in a late-stage study for advanced head and neck cancer, the London-listed drugmaker said on Friday....
Read more

Astellas gets FDA green light for Xospata

Dec 08, 2018 , Drug Store News - Retail
Xospata's approval marks the first FLT3-targeting therapy for acute myeloid leukemia. Read More...
Read more

Gene Therapy for Sickle Cell Takes Another Step Forward

Dec 07, 2018 , MedicineNet
Title: Gene Therapy for Sickle Cell Takes Another Step ForwardCategory: Health NewsCreated: 12/4/2018 12:00:00 AMLast Editorial Review: 12/5/2018 12:00:00...
Read more

Roche's lung cancer combo treatment wins FDA approval

Dec 07, 2018 , Reuters
Swiss drugmaker Roche Holding AG said on Thursday that its Tecentriq immunotherapy in combination with chemotherapy was approved by the U.S. Food and Drug Administration as a first-line treatment for a form of lung cancer....
Read more
Demo

Lower-Dose Tamoxifen Works As Well As High-Dose

Dec 07, 2018 , WebMD
New research shows that a lower dose of the hormone therapy Tamoxifen is as effective as the higher dose treatment in helping to prevent breast cancer from returning and guarding against new cancers in women who had high-risk breast...
Read more

Targeted Drug Plus Hormone Therapy Stops Tumor Growth In Patients With Early Breast Cancer

Dec 07, 2018 , Forbes
A targeted cancer drug added to hormone therapy has been shown to stunt cancer growth in women with newly diagnosed breast...
Read more

AbbVie halts late-stage trial for lung cancer drug Rova-T

Dec 06, 2018 , Reuters
AbbVie Inc said on Wednesday it had halted enrollment for a late stage trial of Rova-T as a second-line therapy for advanced small-cell lung cancer, following recommendations made by an independent data monitoring committee....
Read more

Gene Therapy For Blood Disorders

Dec 06, 2018 , NewsLine - Healthcare Professionals
Gene therapy holds a lot of promise in medicine. If we could safely alter our own DNA, we might eliminate diseases our ancestors passed down to us. Now, a team of University of Delaware researchers has demonstrated a major step forward in gene therapy by engineering microparticles that deliver ge......
Read more

Roche's Tecentriq wins speedy U.S. FDA review for small cell lung cancer

Dec 06, 2018 , Reuters
Swiss group Roche Holding AG said on Wednesday its Tecentriq immunotherapy mixed with chemotherapy won priority review from the U.S. regulator for treating a type of lung cancer, a potential boost to the drug that has been trailing rivals' revenues....
Read more

Drug Halves Recurrence for Common Breast Cancer

Dec 06, 2018 , WebMD
All of the women in the new trial had undergone a standard treatment scenario. First, they received traditional chemotherapy and the drug Herceptin (trastuzumab) -- an antibody that targets HER2-positive cancer cells. Then they had surgery to remove any remaining...
Read more
Demo

The Future Of Cancer Care: A 50 Minute Discussion At Forbes

Dec 06, 2018 , Forbes
The future of cancer therapy, an analysis of how Immunotherapy has improved oncology outcomes for patients. This year's Forbes Summit highlighted both the difficulties, advancements and needs of the cancer care community in order to find the "cure" for...
Read more

Sickle Cell Gene Therapy Makes Another Advance

Dec 05, 2018 , WebMD
The therapy targets the genetic flaw that causes sickle cell. In a small group of patients, researchers said the therapy appears safe and effective enough to keep moving forward into larger...
Read more

Hypnosis could help irritable bowel syndrome symptoms

Dec 05, 2018 , Reuters
(Reuters Health) - Patients with irritable bowel syndrome may find that hypnotherapy helps them cope with their symptoms, a new study shows....
Read more

Roche's Tecentriq wins speedy U.S. review in small cell lung cancer

Dec 05, 2018 , Reuters
Roche's Tecentriq immunotherapy with chemotherapy won priority review in the United States for the initial treatment of extensive-stage small cell lung cancer (SCLC), the company said, setting up possible approval by March 18....
Read more

Norway biotech Ultimovacs plans IPO to develop cancer drug

Dec 04, 2018 , Reuters
Norway's Ultimovacs plans to raise around 700 million Norwegian crowns ($82 million) in an initial public offering in early 2019 to help fund the development of its immunotherapy cancer drug....
Read more

Dutch firm argenx, J&J affiliate to collaborate on cancer therapy

Dec 04, 2018 , Reuters
Netherlands-based biopharmaceutical company argenx SE said it signed a deal with Cilag GmbH International, an affiliate of Johnson & Johnson's Janssen Pharmaceutical Companies unit, to develop its Cusatuzumab drug in certain types of cancer....
Read more

CAR-T Cell Update: Therapy Improves Outcomes For Patients With B-Cell Lymphoma

Dec 04, 2018 , NewsLine - Healthcare Professionals
In their phase-2 study of tisagenlecleucel (marketed as KYMRIAH®), to be published on-line Dec. 1, 2018 in the New England Journal of Medicine, an international team of researchers evaluated 93 patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). They found that 52% of those p......
Read more

Penn Study Shows Regular Behavioral Counseling Leads To Clinically Significant Weight Loss

Dec 04, 2018 , NewsLine - Healthcare Professionals
Intensive behavioral therapy (IBT), which provides diet and physical activity counseling, is proven to help adults with obesity achieve meaningful weight loss in six to 12 months. A new Penn Medicine study, published in Obesity, the journal of the Obesity Society, is the first randomized controlled ......
Read more

High-cost Gilead cell therapy proves durable for some lymphoma patients

Dec 03, 2018 , Reuters
Nearly 40 percent of lymphoma patients treated with a single infusion of Gilead Sciences Inc's Yescarta were still responding to the cell therapy after at least two years of follow-up, the company said on Sunday....
Read more